Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
BELLINGS Intelligence Score: 8
Why it matters
This is routine equity investment analysis comparing two healthcare stocks, with no direct impact on credit markets or lending conditions.